Guo Jianfeng, Zou Yifang, Huang Leaf
School of Pharmaceutical Sciences, Jilin University, Changchun, 130021, China.
Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA.
Small Methods. 2023 May;7(5):e2201307. doi: 10.1002/smtd.202201307. Epub 2023 Jan 5.
Immunogenic cell death (ICD, also known as immunogenic apoptosis) of malignant cells is confirmed to activate the host immune system to prevent, control, and eliminate tumors. Recently, a range of chemotherapeutic drugs have been repurposed as ICD inducers and applied for tumor immunotherapy. However, several hurdles to the widespread application of chemotherapeutic ICD inducers remain, namely poor water solubility, short blood circulation, non-specific tissue distribution, and severe toxicity. Recent advances in nanotechnology and pharmaceutical formulation foster the development of nano drug delivery systems to tackle the aforementioned hurdles and expedite safe, effective, and specific delivery. This review will describe delivery barriers to chemical ICD inducers and highlight recent nanoformulations for these drugs in tumor immunotherapy.
恶性细胞的免疫原性细胞死亡（ICD，也称为免疫原性凋亡）已被证实可激活宿主免疫系统以预防、控制和消除肿瘤。最近，一系列化疗药物已被重新用作ICD诱导剂并应用于肿瘤免疫治疗。然而，化疗ICD诱导剂广泛应用仍存在一些障碍，即水溶性差、血液循环时间短、组织分布非特异性以及毒性严重。纳米技术和药物制剂的最新进展促进了纳米药物递送系统的发展，以克服上述障碍并加快安全、有效和特异性递送。本综述将描述化学ICD诱导剂的递送障碍，并重点介绍这些药物在肿瘤免疫治疗中的最新纳米制剂。
